alexa
Reach Us +1-217-403-9671
CHALLENGES IN THE DESIGN OF COMPARATIVE BIOAVAILABILITY STUDIES - AN INDUSTRY PERSPECTIVE | 8420
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

CHALLENGES IN THE DESIGN OF COMPARATIVE BIOAVAILABILITY STUDIES - AN INDUSTRY PERSPECTIVE

International Conference & Exhibition Bioequivalence and Bioavailability

Dr. Siddarth Chachad

ScientificTracks Abstracts: J Bioequiv Availab

DOI: 10.4172/0975-0851.1000001

Abstract
I n anticipation of the patent expiry of the innovator pharmaceutical product, pharma companies develop generic equivalents with formulation and pharmaceutical properties as close as possible to the original Innovator product. In case of such regulatory submissions, comparative bioavailability studies are required so as to demonstrate bioequivalence between the generic and innovator products. The maximum concentration in plasma and area under the curve are primary parameters of such bioequivalence studies. Although conventional bioequivalence studies can be designed for most drugs, in the era of complexly characterized Liposomal and biotechnology drugs, the study designs of comparative bioavailability studies become further more complex. Challenges in designing such studies include analysis of drugs having low systemic bioavailability, nature of some drugs such as cytotoxic drugs which require studies in patients and not healthy volunteers; and pharmacokinetics of certain drugs which is non-linear. Issues whether to analyze parent drug or metabolite, whether to use single unit or multiple units, crossover or parallel truncated design, sample size rationale, high intraindividual variability and lack of clarity in the regulatory guidance present further challenge in designing comparative bioavailability studies.
Biography
Top